Rare Kidney Diseases Global Market Report 2024

The rare kidney diseases market size has grown rapidly in recent years. It will grow from $2.52 billion in 2023 to $2.8 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The increase observed in the historical period can be attributed to heightened disease recognition, designations of orphan drugs, increased patient advocacy and awareness, and global collaborations in research.

The rare kidney diseases market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period can be attributed to the emergence of gene therapies, a rise in investment in rare disease research, increased collaboration between stakeholders, and global initiatives for rare diseases. Noteworthy trends expected during the forecast period include a patient-centric approach, the utilization of real-world evidence and data analytics, regulatory developments, the integration of telemedicine and remote monitoring, and the implementation of global health initiatives.

The anticipated growth of the rare kidney disease market is expected to be propelled by government initiatives and funding for kidney disorders. Government support, in the form of financial assistance, is directed towards entities with projects and ideas that contribute to improving public services and the economy. Specifically, in July 2022, The United States House Committee on Appropriations initiated various investment programs to promote kidney health, allocating $8.5 million for the Centers for Disease Control and Prevention's chronic kidney disease program. This funding aims to accelerate efforts in raising awareness, diagnosis, and treatment of kidney disease. Additionally, a $1 million investment was earmarked for the national living donor assistance center, totaling $8 million in ongoing investment in innovation and research. Thus, government initiatives and funding are key drivers of growth in the rare kidney disease market.

The significant increase in the prevalence of chronic kidney disease (CKD) is a substantial contributor to the growth of the rare kidney disease market. CKD, characterized by kidney damage and impaired blood filtering, elevates the risk of developing rare kidney diseases. According to the 2023 report from the Centers for Disease Control and Prevention (CDC), approximately 14% of US adults, around 35.5 million people, are estimated to have chronic kidney disease. This rise in CKD prevalence is expected to lead to an increased demand for therapeutics addressing rare kidney diseases, thereby driving the market's expansion.

Innovation in product development stands out as a prominent trend gaining traction in the rare kidney disease market. Major players in the market are strategically focusing on creating innovative products to fortify their market positions. For example, in September 2022, STADA Arzneimittel AG introduced Kinpeygo (budesonide), the first EU-authorized medicine for treating a rare kidney disease, specifically immunoglobulin A nephropathy (IgAN). This modified-release budesonide capsule represents a significant advancement in addressing the high unmet need in primary IgAN, a rare autoimmune kidney disease with a considerable impact on patients.

Companies operating in the rare kidney disease market are specifically emphasizing the development of non-immunosuppressive therapy. This unique treatment approach caters to patients with progressive kidney diseases, offering an alternative to traditional therapies for rare kidney diseases. For instance, in February 2023, Travere Therapeutics launched sparsentan, commercially known as Filspari, the first non-immunosuppressive therapy approved for primary immunoglobulin A nephropathy (IgAN). Filspari operates through a distinct mode of action by blocking angiotensin and endothelin receptors, setting it apart from conventional treatments such as ACE inhibitors and ARBs.

In February 2023, AstraZeneca Pharmaceuticals LP acquired CinCor Pharma Inc. for $1.8 billion. This acquisition positions AstraZeneca Pharmaceuticals LP to enhance its portfolio in chronic renal illness and uncontrolled hypertension, as CinCor Pharma Inc. brings valuable medications for rare kidney diseases to the company's offerings.

Major companies operating in the rare kidney diseases market report are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline PLC, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Proteostasis Therapeutics, Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., Spyryx Biosciences Inc., OxThera AB, Advicenne Pharma SA, ProQR Therapeutics NV, Reata Pharmaceuticals Inc., Savara Inc.

North America was the leading region in the rare kidney disease market in 2023. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare kidney diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary target indications for rare kidney diseases include IgA nephropathy, lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy, C3 glomerulopathy, and others. IgA nephropathy is a kidney disease characterized by the accumulation of antibodies (known as IgA) in kidney tissue, leading to inflammation. Treatment involves the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to lower blood pressure, reduce protein loss, slow the progression of kidney damage, manage symptoms, and prevent complications. The various types of molecules involved in treatment include small molecules and biologics, which are administered through various routes such as oral, intravenous, subcutaneous, and others.

The rare kidney diseases market research report is one of a series of new reports that provides Rare Kidney Diseases market statistics, including Rare Kidney Diseases industry global market size, regional shares, competitors with a Rare Kidney Diseases market share, detailed Rare Kidney Diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the Rare Kidney Diseases industry. This Rare Kidney Diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare kidney disease market includes revenues earned by entities by providing services clinical evaluation, genetic counseling, genetic screening, specific testing, molecular diagnosis, hemodialysis, and peritoneal dialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.